DDInter1000 DDInter1658
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medic
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Ivosidenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Ivosidenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Ivosidenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Ivosidenib {u} may lead to a major life threatening interaction when taken with {v} Alfuzosin
Ivosidenib {u} may lead to a major life threatening interaction when taken with {v} Oliceridine
Ivosidenib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Ivosidenib may lead to a major life threatening interaction when taken with Alfuzosin
Ivosidenib may lead to a major life threatening interaction when taken with Oliceridine